# 1st Gen Model Zoetis Inc. Pharmaceutical preparations

Subscribe >> Deal exit on
Dec. 15, 2017
Deal entry on
Dec. 15, 2017
0.38%Expected margin
79.17% successful of 48 deals
$71.96 Last close price
at 15-dec-2017

ZTS

Model's trade recommendations No return for period yet

9.18% Annual return

$35.27B Market Cap

β 1.06  

ZTS

Model (following trade recommendations)

ZTS

Underlying stock

S&P 500

Index
Return for period
1.65%
1.78%
52wk return 10.22%
37.17%
16.82%
52wk Range
52.39—72.38
2000.54—2399.63
Sortino ratio 1.46
Sharpe ratio 1.04
Norm. RMSE 0.34%
Downside risk 6.03%
Volatility 8.48%
  • 0.42 (0.58%) Div (Yield)
  • STRONG BUY Analysts consensus recommendation

Zoetis discovers, develops, manufactures and markets veterinary vaccines and medicines, complemented by diagnostic products and genetic tests and supported by a range of services.

Industry sector: Medical

Sector classification: Pharmaceutical preparations

Deep Learning based analysis and prediction model for Zoetis Inc. (ZTS) stock is a 1st Generation Non-linear Autoregresive with exogenous variable(s) (NARX) model based on the Recurrent Neural Network architecture.

Model is in the production pipeline since Oct. 22, 2015.

Market data for ZTS model training are being downloaded from the Quandl premium datasets on a daily basis.

Model is being retrained on a daily basis.

Float 486M
P/E 33.20
Shares Outstanding 487M
% Held by Insiders 0.31%
% Held by Institutions 93.33%
EPS (last reported FY) $1.96
EPS (last reported Q) $0.65
EPS, estimated (last reported Q) $0.63
Total revenues $5 B
Net income $1 B